^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Senl_H19x22P

    i
    Other names: Senl_H19x22P
    Associations

    News

    Trials
    Company:
    SenlangBio
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    almost3years
    Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Hebei Senlang Biotechnology Inc., Ltd.
    New trial • CAR T-Cell Therapy
    |
    CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD22 (CD22 Molecule) • IL10 (Interleukin 10)
    |
    CD20 positive • CD19 expression
    |
    Senl_H19x22P
    4years
    CAR-T Cells in Treating Patients With Relapsed or Refractory NHL (clinicaltrials.gov)
    P1, N=100, Recruiting, Hebei Senlang Biotechnology Inc., Ltd.
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD20 positive • CD19 positive
    |
    fludarabine IV • Senl_H19x22P